Skip to main content
JIUZHITANG CO.,LTD logo

JIUZHITANG CO.,LTD — Investor Relations & Filings

Ticker · 000989 ISIN · CNE000001394 LEI · 3003004OFW6FCZ34KN72 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,885 across all filing types
Latest filing 2022-05-06 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 000989

About JIUZHITANG CO.,LTD

https://www.hnjzt.com

JIUZHITANG CO.,LTD. is a pharmaceutical enterprise specializing in the research, development, manufacturing, and distribution of Traditional Chinese Medicine (TCM). Established in 1650, the company is recognized as a time-honored brand with a heritage spanning over three centuries. Its core product portfolio includes a diverse range of TCM formulations, most notably Liuwei Dihuang Wan, donkey-hide gelatin (Ejiao), and various health supplements focused on chronic disease management and general wellness. The company operates modern production facilities that integrate traditional processing techniques with contemporary scientific standards and biotechnology. JIUZHITANG focuses on the modernization of TCM through clinical research and innovation, maintaining a distribution network that serves retail pharmacies and medical institutions to provide natural healthcare solutions.

Recent filings

Filing Released Lang Actions
关于召开2021年度业绩说明会并征集问题的公告
Investor Presentation Classification · 95% confidence The document is a short announcement (814 characters) about the scheduling of a 2021 annual performance explanation meeting (业绩说明会) to be held online on May 16, 2022. It references that the 2021 annual report was disclosed on April 23, 2022, but this document itself does not contain any financial data or the report itself. It invites investors to submit questions for the meeting. This is clearly an announcement about an investor presentation event rather than the presentation or report itself. According to the classification rules, such announcements about upcoming investor presentations are best classified as Investor Presentation (IP) if they contain the presentation itself, or Report Publication Announcement (RPA) if they announce a report release. However, since this is about an upcoming performance explanation meeting (业绩说明会) and soliciting questions, it aligns best with Investor Presentation (IP) category as it relates to a detailed presentation for investors focusing on financials and strategy, even though the presentation is to be held in the future. The document is not a report publication announcement (RPA) because it is not announcing the release of a report but the meeting event. Therefore, the best fit is Investor Presentation (IP).
2022-05-06 Chinese
第八届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the 9th meeting of the 8th Board of Directors of Jiuzhitang Co., Ltd. It details the approval of a related-party transaction involving the transfer of subsidiary shares and mentions voting results and independent director opinions. The document is short (1210 characters) and serves as a formal announcement of board decisions rather than a full management report or financial statement. It does not contain financial data or detailed management discussion but focuses on board meeting resolutions and voting outcomes. Therefore, it fits the category of Board/Management Information (MANG).
2022-04-24 Chinese
关于控股股东协议转让公司部分股份的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding the agreement-based transfer of shares by the controlling shareholder of the company. It includes specifics about the share transfer agreement, parties involved, shareholding changes, compliance with regulations, and commitments by the controlling shareholder. The document focuses on a change in major shareholding and provides a simplified report on the equity change. There is no financial statement, earnings data, or management discussion of financial results. The content aligns with a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds.
2022-04-24 Chinese
上海东洲资产评估有限公司-湖南九芝堂医药有限公司股东全部权益价值预估报告
Audit Report / Information Classification · 95% confidence The document is titled as a "预估报告" (valuation or appraisal report) for the total equity value of a company (湖南九芝堂医药有限公司). It is prepared by an asset appraisal company (上海东洲资产评估有限公司) and dated April 24, 2022. The content includes detailed valuation methodology, assumptions, and conclusions about the market value of the company's equity as of December 31, 2021. The document is 2916 characters long, which is relatively short but contains substantive valuation content rather than just an announcement or a link to a report. It is not an annual or interim financial report, nor is it a regulatory filing or announcement. It is a standalone valuation report, which fits best under the category of Audit Report / Information (AR), as it involves an independent valuation and assessment of company equity value, which is a type of audit-related information. Therefore, the most appropriate classification is AR with high confidence. FY 2021
2022-04-24 Chinese
容诚会计师事务所(特殊普通合伙)-湖南九芝堂医药有限公司2021年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed auditor opinions, responsibilities, and a comprehensive audit of the company's financial statements for the year ending December 31, 2021. The text includes auditor certifications, detailed financial statement notes, and audit procedures, which are typical contents of a standalone audit report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is an Annual Report (10-K) or other types of filings. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2021
2022-04-24 Chinese
第八届董事会第九次会议审议事项事前认可函
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the independent directors of a company regarding their prior approval of a board meeting agenda item related to a related-party transaction (transfer of subsidiary shares). It references regulatory rules and confirms the transaction does not harm shareholders. The document is short (595 characters) and is an announcement of a board review and approval process, not a full report or financial statement. It does not contain financial data or detailed management discussion. This fits best under Regulatory Filings (RNS) as it is a compliance announcement related to corporate governance and regulatory requirements, but not a full management or board report or a financial filing.
2022-04-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.